INTRODUCTION
============

Axillary lymph node (ALN) metastasis is one of the most significant prognostic factors for survival in breast cancer patients. Sentinel lymph node dissection (SLND) has become the standard practice for nodal staging in patients with early-stage breast cancer. Several studies revealed that SLND accurately evaluated the status of ALN and was associated with decreased morbidity than axillary lymph node dissection (ALND) in clinically node-negative patients \[[@B1][@B2][@B3]\].

Neoadjuvant chemotherapy (NAC) has become the standard treatment in patients with inoperable locally advanced and large operable breast cancers. It is also widely used in patients with early invasive breast cancer. Rates of pathologic complete remission (pCR) vary from 16% to 20% according to the histologic subtypes of tumor and treatment modalities \[[@B4][@B5][@B6]\]. Achievement of pCR has been correlated with better disease-free survival and overall survival \[[@B7][@B8][@B9]\].

ALN metastases can be eradicated by NAC and the initial nodal stage will change substantially after NAC \[[@B10][@B11]\]. Residual metastatic ALNs after NAC are important prognostic factor for disease-free survival \[[@B12][@B13]\], and lymph nodes involvement at the time of surgery, not the initial axillary node stage, is significantly associated with distant disease-free survival \[[@B14]\].

Dynamic contrast-enhanced magnetic resonance imaging (MRI) is known to be the most accurate diagnostic tool for the assessment of tumor response after NAC \[[@B15][@B16]\]. On maximum intensity projection (MIP) images of MRI, it is easier and more accurate to measure the longest dimension of primary tumor than mammography or ultrasound (US).

The purpose of our study was to find out any histologic factors associated with negative conversion of ALN after NAC. We also evaluated the association between the decrease of primary breast tumor and negative conversion of ALN.

METHODS
=======

Patients
--------

Our Institutional Review Board approved this retrospective study (MED-MDB-14-476). From January 2012 to November 2014, 191 consecutive patients with breast cancer underwent NAC. Of 191 patients, 139 patients had ALN metastases which were confirmed on fine-needle aspiration or core needle biopsy at initial diagnosis. We excluded three patients who did not undergo follow-up MRI, one patient who underwent vacuum assisted biopsy in the outside hospital before initial MRI, and two patients who had human epidermal growth factor receptor 2 (HER2)-positive cancer but did not receive trastuzumab treatment. Finally 133 patients were included for the analysis. Patient characteristics are summarized in [Table 1](#T1){ref-type="table"}. ALND was performed in 127 patients regardless of SLN status. ALND was omitted in six patients who had converted to clinically negative ALN, near complete remission of primary breast tumor on imaging after NAC and had confirmed negative SLN on pathology.

All patients were scheduled for four cycles of adriamycin and cyclophosphamide (AC) regimen (AC, 50 mg/m^2^ and 500 mg/m^2^, respectively) followed by four cycles of paclitaxel 175 mg/m^2^ at a 3-week interval. Of 133 patients, 12 patients underwent the operation after four cycles of NAC because of complete remission of primary breast tumor on MRI (n=3), disease progression (n=2) or little response to NAC (n=7). All 30 patients who had HER2-positive cancer received trastuzumab treatment.

MRI technique and interpretation
--------------------------------

Patients underwent MR examinations three times, at the time of initial diagnosis, after four cycles of adriamycin and cyclophosphamide and after four cycles of paclitaxel. We used a 1.5-T MR system (Signa HDxt; General Electric Medical Systems, Milwaukee, USA) with a dedicated breast coil (8-channel HD breast array; General Electric Medical Systems). An unenhanced coronal fast low-angle shot three-dimensional T1-weighted image was acquired. Gadobutrol (Gadovist; Bayer Schering Pharma, Berlin, Germany) was injected into an antecubital vein at a dose of 0.1 mmol/kg of body weight and at a rate of 3 mL/sec, followed by a 20-mL saline flush for all patients. Subsequently, five consecutive contrast-enhanced series were acquired. The imaging parameters were repetition time (msec)/echo time (msec) of 5.1/2.4, flip angle of 10°, field of view of 300×300 mm, image matrix of 300×300 pixels, section thickness of 1.5 mm, and section gap of 0 mm.

Subtraction images were reconstructed by subtracting the precontrast images from the early peak postcontrast image obtained at 60 seconds after contrast injection. MIP reconstructions were applied to the subtraction images. Two radiologists with 11 and 7 years\' experiences interpreted MRI before and after NAC in consensus. The lesion size was measured as the longest diameter of the lesion on MIP image. In patients with multiple cancers, we recorded the sum of the longest diameter of each lesion.

Pathologic examination
----------------------

All patients underwent core needle biopsy before surgery and surgical resection for breast cancer with sentinel lymph node biopsy (SLNB) and/or axillary lymph node dissection after NAC. The localization of primary tumor was performed by charcoal injection after four cycles of NAC. The routinely formalin-fixed, paraffin-embedded tissue blocks of tumors and ALNs were sectioned to 4 µm thickness and stained with hematoxylin and eosin.

The specimens of core needle biopsy were evaluated according to the following histopathologic features: histological type of carcinoma, Black nuclear grade (nuclear grade 1, poorly differentiated; grade 2, moderately differentiated; and grade 3, well differentiated), and modified Bloom-Richardson histological grade (histological grade 1, well differentiated; grade 2, moderately differentiated; and grade 3, poorly differentiated). For dichotomous-dependent variables, nuclear grade was classified as high (grade 1) versus low (grades 2 and 3) and histologic grade as low (grade 1 and 2) versus high (grade 3). Expression of estrogen receptor (ER), progesterone receptor (PR), and HER2 was evaluated using standard avidin-biotin complex immunohistochemical staining methods. The ER and PR status were assessed using the Allred score, which was expressed as the sum of the proportion score and the intensity score of positively stained tumor cells. Tumors with an Allred score of at least 3 were regarded as positive. The intensity of HER2 staining was scored as 0, 1+, 2+, or 3+. Tumors with a 3+ score were classified as HER2 positive, and tumors with a 0 or 1+ score were classified as negative. In tumors with a 2+ score, gene amplification by using fluorescence *in situ* hybridization was used to determine HER2 status.

After completion of NAC, the size and extent of residual cancer were measured. The pCR was defined as the complete disappearance of invasive carcinoma in the breast. Residual ductal carcinoma *in situ* (DCIS) was included in the pCR category. All specimens were reviewed by an experienced pathologist with 16 years of experience.

Statistical analysis
--------------------

The mean values of initial tumor size, percent decrease in longest dimension and duration of NAC were compared using two-sample t-test. Univariate analysis was performed by using chi-square and Fisher exact test for the evaluation of relationships between ALN status with clinical and histopathologic factors. Multivariate analysis was performed using logistical regression of the variables that were found to be statistically significant on univariate analyses. Analyses were performed using the SPSS version 19.0 statistical software package (IBM Corp., Armonk, USA), with a value of *p*\<0.05 considered to be significant.

For the evaluation of diagnostic performance of percent decrease in longest dimension, we used receiver operating characteristic (ROC) analysis. Diagnostic accuracy was calculated from the area under the ROC curve (AUC). The best cutoff was determined from the ROC analysis and we used the best cutoff values to calculate the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for predicting negative conversion of ALN. We used MedCalc software (version 10.4.8; MedCalc Software, Ostend, Belgium) for ROC analysis.

RESULTS
=======

Of 133 patients, 39 patients (29%) showed negative conversion of ALN. Of these 39 patients, 25 patients (64%) showed pCR of primary breast tumor and five patients (13%) had residual tumor less than 5 mm.

Univariate analysis was performed for the evaluation of relationships between the negative conversion of ALN and clinical and histological factors ([Table 2](#T2){ref-type="table"}). Mean percent decrease in longest dimension was significantly higher in patients with negative conversion compared to patients with residual metastatic ALN (82% vs. 37%, *p*\<0.001). There were no significant differences in mean initial tumor size, mean duration of NAC treatment and cycles of NAC (*p*=0.145, *p*=0.510, and *p*=0.508, respectively). ER, PR, HER2 status and histologic grade were significantly associated with the ALN status after NAC (*p*=0.001, *p*\<0.001, *p*=0.001, *p*=0.002, respectively). Nuclear grade was not significantly different between two groups (*p*=0.222).

Multivariate logistic regression analysis was performed with the variables associated with axillary lymph node status through univariate analysis ([Table 3](#T3){ref-type="table"}). Percent decrease in longest dimension (odds ratio, 1.026; 95% confidence interval \[CI\], 1.009-1.044) and histologic grade (odds ratio, 3.964; 95% CI, 1.151-13.657) were identified as being independently associated with the ALN status after NAC. ER, PR, and HER2 were not significant independent factor for ALN status after NAC.

A ROC analysis was performed to differentiate negative conversion group from the residual metastasis group by using percent decrease in longest dimension of primary breast tumor ([Figure 1](#F1){ref-type="fig"}). The AUC was 0.835. The best cutoff for differentiating negative conversion group from residual metastatic ALN group was 80% decrease in longest dimension. With this cutoff, percent diameter decrease showed 89.4% sensitivity, 79.5% specificity, 91.2% PPV, and 73.8% NPV.

Diagnostic performance of combination of high histologic grade or more than 80% decrease in longest dimension was assessed for the diagnosis of metastatic ALN after NAC. The sensitivity, specificity, PPV and NPV were 64% (60/94), 92% (36/39), 95% (60/63), and 100% (36/36), respectively.

DISCUSSION
==========

Lymph node status after NAC have known to be an important prognostic factor for disease-free survival \[[@B12][@B13][@B14]\]. In a recent prospective multicenter study \[[@B17]\], detection rate of SLNB was 80.1% and the false-negative rate was 14.2% in patients with lymph node conversion after NAC. The false-negative rate of SLNB was 12.6%, if two or more sentinel lymph nodes were removed and dual agents were used, in patients with breast cancer with clinical N1 stage receiving NAC in ACOSOG Z1071 trial \[[@B18]\].

However, the detection rate of SLNB after NAC is limited by the effects of NAC, including anatomical alterations or disruptions of lymphatic vessels by tumors, inflammation or fibrosis, blockage by necrotic and/or apoptotic cells or induction of nonuniform tumor regression among ALNs \[[@B19][@B20]\]. In the study of Park et al. \[[@B21]\], patients with poor tumor or nodal response to NAC had higher SLN detection failure rates. They suggested that disruption or blockage of lymphatic pathways by residual tumors might affect the detection rate of radioisotope-based SLNB. Thus, accurate prediction of ALN status before surgery is important because it could help surgeons to proceed directly to ALND or to do SLNB without ALND.

In a recent study analyzing the diagnostic performance of US, MRI, and F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) for metastatic lymph node after NAC, the sensitivity was 70%, 61%, and 63% and the specificity was 58%, 59%, and 85%, respectively \[[@B22]\]. In a recent review article, the sensitivity of US, MRI, and PET/CT was 58%-86%, 59%, and 48-85%, respectively for the detection of pathologic complete remission of ALN \[[@B23]\]. Previous result of our institution revealed that the sensitivity of US, MRI, and PET/CT was 50%, 72%, and 22% and the specificity of US, MRI, and PET/CT was 77%, 54%, and 85%, respectively \[[@B24]\].

Add of axillary ultrasound (AUS) to SLNB could reduce the false-negative rate from 12.6% to 9.8% in ACOSOG Z1071 trial \[[@B25]\]. In this study, patients with suspicious LNs on AUS had a greater number of positive LNs and larger size of metastasis in ALN and the negative predictive value of AUS was 43% (145/334). In our study, by using the combination of high histologic grade or more than 80% decrease in longest dimension, the PPV and NPV were very high, 95% and 100% for the diagnosis of metastatic ALN. Thus, high PPV could be useful in routine practice for surgeons to proceed to ALND without SLNB and high NPV for surgeons to do only SLNB without ALND.

There are several studies reporting the association of ALN status and the pathologic primary tumor response to NAC. In the study of Nagashima et al. \[[@B26]\], response rate of primary breast tumor was correlated with that of lymph node and these were well correlated with disease-free survival. However, tumor size, histological grade and HER2 were not correlated with patient outcome. In the study of Rouzier et al. \[[@B14]\], high histologic grade and more than 50% response to chemotherapy were associated with negative conversion of ALN after NAC. Our results also showed that high histologic grade and better response of primary breast tumor were associated with negative conversion of ALN.

In the study of Kuerer et al. \[[@B27]\], of 30 patients with pCR of primary breast tumor, 19 patients (63%) had negative ALN at dissection. Thirteen patients (33%) of 40 who had near pCR (residual cancer ≤1 cm^3^) and 15 patients (17%) of 86 who had residual cancer larger than 1 cm^3^ showed negative ALN at dissection. Our results also revealed that mean percent decrease in longest dimension was significantly higher in patients with negative conversion compared to patients with residual metastatic ALN (82% vs. 37%, *p*\<0.001). With 80% cutoff value, percent diameter decrease showed 89.4% sensitivity, 79.5% specificity, 91.2% PPV, and 73.8% NPV for the diagnosis of metastatic ALN after NAC.

There are several limitations in our study. First, this was a retrospective study from a single center and the total number of patients was relatively small. Larger multicenter study with more patients is needed to validate our results. Second, we did not evaluate the recurrence of ALN after surgery because of relatively short duration of follow-up. The follow-up study of ALN recurrence is needed for better understanding of cancer biology after NAC.

In conclusion, high histologic grade and more than 80% decrease in primary tumor dimension were associated with negative conversion of ALN after NAC.
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![Receiver operating characteristic (ROC) analysis in the differentiation of negative conversion group and residual metastasis group. Area under the ROC curve of percent decrease in longest dimension is 0.835. The best cutoff value is 80% decrease in longest dimension.](jbc-18-394-g001){#F1}

###### Patient and tumor characteristics (n=133)

![](jbc-18-394-i001)

  Characteristic          No. (%)
  ----------------------- ------------
  Age (yr)^\*^            46.4±9.9
  Tumor size (cm)^\*^     3.8±2.2
  T stage                 
   T1                     23 (17.3)
   T2                     76 (57.1)
   T3                     13 (9.8)
   T4                     21 (15.8)
  Tumor histology         
   Invasive ductal        126 (94.7)
   Invasive lobular       3 (2.3)
   Others                 4 (3.0)
  Nuclear grade           
   Low                    53 (49.5)
   High                   54 (50.5)
  Histologic grade        
   Low                    70 (64.8)
   High                   38 (35.2)
  Estrogen receptor       
   Negative               40 (30.1)
   Positive               93 (69.9)
  Progesterone receptor   
   Negative               64 (48.1)
   Positive               69 (51.9)
  HER2                    
   Negative               103 (77.4)
   Positive               30 (22.6)

HER2=human epidermal growth factor receptor 2.

^\*^Mean±SD.

###### Association of axillary lymph node status after neoadjuvant chemotherapy with clinical and histopathologic prognostic factors

![](jbc-18-394-i002)

  -----------------------------------------------------------------------------------------------------
  Pathologic factor                       Negative ALN (n = 39)\   Positive ALN (n = 96)\   *p*-value
                                          No. (%)                  No. (%)                  
  --------------------------------------- ------------------------ ------------------------ -----------
  Initial tumor size (cm)^\*^             4.2 ± 2.22               3.62 ± 2.22              0.145

  Decrease in longest dimension (%)^\*^   81.79 ± 35.57            36.66 ± 31.11            \< 0.001

  Duration of NAC (mo)^\*^                5.95 ± 1.52              5.71 ± 2.00              0.510

  NAC cycles                                                                                0.508

   4 cycles                               2 (5.1)                  10 (10.6)                

   8 cycles                               37 (94.9)                84 (89.4)                

  Estrogen receptor                                                                         0.001

   Negative                               20 (51.3)                20 (21.3)                

   Positive                               19 (48.7)                74 (78.7)                

  Progesterone receptor                                                                     \< 0.001

   Negative                               29 (74.4)                35 (37.2)                

   Positive                               10 (25.6)                59 (62.8)                

  HER2                                                                                      0.001

   Negative                               23 (59.0)                80 (85.1)                

   Positive                               16 (41.0)                14 (14.9)                

  Nuclear grade                                                                             0.222

   Low                                    7 (36.8)                 46 (52.3)                

   High                                   12 (63.2)                42 (47.7)                

  Histologic grade                                                                          0.002

   Low                                    7 (35.0)                 63 (71.6)                

   High                                   13 (65.0)                25 (28.4)                
  -----------------------------------------------------------------------------------------------------

ALN=axillary lymph node; NAC=neoadjuvant chemotherapy; HER2=human epidermal growth factor receptor 2.

^\*^Mean±SD.

###### Logistic regression analysis for variables associated with negative conversion of axillary lymph node

![](jbc-18-394-i003)

  Variable                                β        Standard error   Odds ratio   95% CI         *p*-value
  --------------------------------------- -------- ---------------- ------------ -------------- -----------
  Percent decrease in longest dimension   0.026    0.009            1.026        1.009-1.044    0.004
  Estrogen receptor                       0.536    0.758            1.710        0.387-7.557    0.479
  Progesterone receptor                   -0.848   0.738            0.428        0.101-1.820    0.251
  HER2                                    0.224    0.644            1.251        0.354-4.423    0.728
  Histologic grade                        1.377    0.631            3.964        1.151-13.657   0.029

CI=confidence interval; HER2=human epidermal growth factor receptor 2.
